Boston Scientific Corporation (BSX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Boston Scientific Corporation (BSX) Healthcare & Pipeline Overview

Boston Scientific Corporation excels in the development and manufacturing of innovative medical devices, addressing critical healthcare needs across multiple specialties, including cardiovascular, rhythm management, and surgical interventions, while maintaining a robust market presence and a commitment to improving patient outcomes.

What Is the Investment Thesis for BSX?

Boston Scientific Corporation is poised for continued growth driven by its robust product pipeline and strategic focus on innovation. The company has a market capitalization of $77.3B and a P/E ratio of 11.9, reflecting investor confidence in its long-term prospects. Key value drivers include a profit margin of 17.2% and a gross margin of 70.4%, which indicate operational efficiency and strong pricing power. Growth catalysts include the increasing demand for minimally invasive procedures, advancements in cardiac and neurological technologies, and expansion into emerging markets. However, potential risks include regulatory challenges and competition from other industry players.

Based on FMP financials and quantitative analysis

BSX Key Highlights

Market capitalization of $77.3B, indicating a strong market presence.

• P/E ratio of 11.9, reflecting investor confidence in growth potential.
• Profit margin of 17.2%, showcasing operational efficiency.
• Gross margin of 70.4%, exceeding industry averages and indicating strong pricing power.
• A workforce of 53,000 employees, underscoring the company's scale and operational capabilities.

Who Are BSX's Competitors?

BSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BSX's Key Strengths?

Strong market position with a diverse product portfolio.

• High gross margins indicating operational efficiency.
• Commitment to innovation through significant R&D investment.
• Established global presence with a wide distribution network.

What Are BSX's Weaknesses?

Dependence on a limited number of product lines for revenue.

• Exposure to regulatory challenges and compliance risks.
• Potential for product recalls impacting brand reputation.
• High competition leading to pricing pressures.

What Could Drive BSX Stock Higher?

BSX catalyst: Continued expansion of the product pipeline with new medical devices expected to launch in the next 12 months.

• Strong demand for minimally invasive procedures driving sales growth across multiple segments.
• Strategic partnerships and collaborations enhancing market reach and product development capabilities.
• Anticipated regulatory approvals for new devices that could significantly impact market share.
• Investment in research and development to drive innovation and maintain competitive advantage.

What Are the Key Risks for BSX?

Regulatory challenges that could delay product launches or approvals.

• Intense competition from other medical device manufacturers impacting pricing and market share.
• Economic downturns affecting healthcare budgets and spending on medical devices.
• Supply chain disruptions that could impact product availability and delivery timelines.

What Are the Growth Opportunities for BSX?

• Boston Scientific's innovative products, such as drug-eluting stents and implantable devices, position the company to capture significant market share in this growing segment.
• With its spinal cord stimulation systems and deep brain stimulation technologies, the company is strategically positioned to meet the increasing demand for chronic pain management solutions.
• Growth opportunity 3: The global market for minimally invasive surgical devices is anticipated to grow at a CAGR of 6.5% through 2026, reaching $50 billion. Boston Scientific's commitment to developing innovative MedSurg products places it in a favorable position to benefit from this trend, particularly in gastrointestinal and urological applications.
• Growth opportunity 4: The expansion into emerging markets, particularly in Asia-Pacific and Latin America, offers significant growth potential. As healthcare infrastructure improves and access to advanced medical technologies increases, Boston Scientific can leverage its expertise to penetrate these markets effectively.
• Growth opportunity 5: The increasing focus on remote patient management and telehealth solutions is expected to drive growth in the healthcare sector. Boston Scientific's investment in remote monitoring technologies positions it to capitalize on this trend, enhancing patient engagement and improving clinical outcomes.

What Opportunities Does BSX Have?

• Growth in emerging markets offering new revenue streams.
• Increasing demand for minimally invasive surgical procedures.
• Expansion of remote patient management technologies.
• Strategic acquisitions to enhance product offerings and market reach.

What Are BSX's Competitive Advantages?

• Strong brand recognition and reputation for quality and innovation.
• Extensive patent portfolio protecting proprietary technologies.
• Established relationships with healthcare providers and institutions.
• Robust research and development capabilities driving continuous innovation.
• Diverse product portfolio catering to multiple medical specialties.

What Does BSX Do?

Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation has established itself as a global leader in the development, manufacturing, and marketing of medical devices. The company operates through three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Boston Scientific's extensive product portfolio includes devices for diagnosing and treating gastrointestinal and pulmonary conditions, as well as products for urological and pelvic conditions. The company is also known for its implantable cardioverter defibrillators, pacemakers, and advanced remote patient management systems. Over the years, Boston Scientific has expanded its offerings to include cutting-edge technologies for cardiac mapping, navigation solutions, and spinal cord stimulation systems for chronic pain management. The company has continually adapted to the evolving healthcare landscape, focusing on innovation and patient-centric solutions. With a workforce of approximately 53,000 employees, Boston Scientific serves a diverse global market, providing essential medical technologies that enhance patient care and improve clinical outcomes. The company's commitment to research and development has positioned it favorably within the competitive landscape, allowing it to maintain a strong foothold in the rapidly growing medical device industry.

What Products and Services Does BSX Offer?

• Develops and manufactures medical devices for various interventional specialties.
• Offers products for diagnosing and treating gastrointestinal and pulmonary conditions.
• Provides implantable devices for cardiac rhythm management.
• Delivers advanced technologies for spinal cord stimulation and chronic pain management.
• Markets interventional cardiology products, including stents and catheters.
• Focuses on innovative solutions to improve patient outcomes and enhance healthcare delivery.

How Does BSX Make Money?

• Generates revenue through the sale of medical devices across multiple therapeutic areas.
• Operates through three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
• Invests in research and development to drive innovation and expand product offerings.
• Utilizes a global distribution network to reach healthcare providers and patients.
• Focuses on partnerships and collaborations to enhance product development and market reach.

What Industry Does BSX Operate In?

The medical device industry is experiencing significant growth, driven by technological advancements, an aging population, and increasing demand for minimally invasive procedures. Boston Scientific Corporation is well-positioned within this competitive landscape, facing competition from established players such as Amgen Inc. (AMGN), Gilead Sciences, Inc. (GILD), Abbott Laboratories (ABT), Pfizer Inc. (PFE), and Danaher Corporation (DHR). The company's focus on innovation and patient-centric solutions enables it to maintain a competitive edge in a rapidly evolving market.

Who Are BSX's Key Customers?

• Healthcare providers including hospitals and outpatient clinics.
• Physicians and specialists in various medical fields.
• Patients requiring medical interventions for chronic conditions.
• Healthcare systems and payers seeking effective medical solutions.
• Distributors and partners in the medical device supply chain.

Boston Scientific Corporation Financial Trajectory

Boston Scientific Corporation (BSX) reported $5.44B in revenue for Q2 2026, reflecting 4.6% growth compared to the prior quarter. The company recorded net income of $907.0M, with diluted EPS of $0.61. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BSX averaged $0.61 in diluted EPS.

Company Profile

Boston Scientific Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Marlborough, US. The company is led by CEO Michael F. Mahoney. BSX has traded publicly since 1992.

How Boston Scientific Corporation Is Valued

Boston Scientific Corporation carries a market capitalization of $77.3B, placing it in the large-cap category. Relative to its peer group, BSX's quantitative score of 80/100 is roughly in line with the peer average of 70/100.

Return on equity for Boston Scientific Corporation stands at 14.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.1%, showing how much profit it generates from its asset base. BSX trades at a trailing price-to-earnings ratio of 11.94, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

Boston Scientific Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.31 places it in the safe zone, indicating low near-term bankruptcy risk.

Boston Scientific Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 5.1% above estimates on average.

Wall Street analysts project Boston Scientific Corporation revenue of about $21.35B for fiscal 2026, with EPS near $3.30. The estimate reflects 21 contributing analysts.

Over the past six months, Boston Scientific Corporation insiders filed 15 SEC Form 4 transactions — 3 sales and 12 purchases. On net that is roughly 89K shares disposed (about $14.3M), a signal worth weighing alongside the fundamentals.

BSX Financials

BSX Latest News

BSX Analyst Consensus

BSX MoonshotScore

Latest Boston Scientific Corporation Analysis

Boston Scientific Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources